In this episode of “Better Biopharma,” host Tyler Menichiello is joined by former FDA staffers Eva Temkin, partner at Arnold & Porter, and Elizabeth Trentacost, senior associate at Arnold & Porter. They reflect on 2026 regulatory developments and discuss the implications and nuances of Operation TrialBlazer. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Su...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Better Biopharma
Focusing On Quality Unit Independence With Tatyana Matveeva, Ph.D.
Developing Multi-Targeted T-Cell Engagers With Deck Bio’s Johanna Kaufmann
Fixing AAV Recovery With Siren Biotechnology’s Nathalie Clément, Ph.D.
Digitalizing The Biopharma Ecosystem With Kat Kozyrytska
Get summaries like this every morning.
Free AI-powered recaps of Better Biopharma and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.